<code id='89BAD2267A'></code><style id='89BAD2267A'></style>
    • <acronym id='89BAD2267A'></acronym>
      <center id='89BAD2267A'><center id='89BAD2267A'><tfoot id='89BAD2267A'></tfoot></center><abbr id='89BAD2267A'><dir id='89BAD2267A'><tfoot id='89BAD2267A'></tfoot><noframes id='89BAD2267A'>

    • <optgroup id='89BAD2267A'><strike id='89BAD2267A'><sup id='89BAD2267A'></sup></strike><code id='89BAD2267A'></code></optgroup>
        1. <b id='89BAD2267A'><label id='89BAD2267A'><select id='89BAD2267A'><dt id='89BAD2267A'><span id='89BAD2267A'></span></dt></select></label></b><u id='89BAD2267A'></u>
          <i id='89BAD2267A'><strike id='89BAD2267A'><tt id='89BAD2267A'><pre id='89BAD2267A'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:3
          James Fanale, the former CEO and president of Care New England, and his wife Deb (left) on their front porch. -- health coverage from STAT
          Courtesy Ryan Pickering

          PROVIDENCE – In late August, Dr. James E. Fanale was trudging through the Falmouth Road Race — walking up the hills, running down them — for seven miles. Fellow runners encouraged him to “keep trying” whenever he slowed down. But they couldn’t have known — along with most of the people in Fanale’s professional orbit — that he was battling Stage 4 lung cancer.

          “Many times, I wanted to say ‘Listen buddy, you don’t know what I’ve got in me,’” Fanale recalled recently with a chuckle.

          advertisement

          In December 2022, on the day Fanale retired as president and CEO of Care New England, he shared his diagnosis with a Globe reporter but requested it be kept private. He was handing the reins to new CEO Dr. Michael Wagner after six years leading the second largest health care system in Rhode Island.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma
          Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

          RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Medicare Advantage enrollment hits roughly 33.4 million

          AdobeYou’rereadingthewebversionofHealthCareInc., STAT’sweeklynewsletter followingtheflowofmoneyinmed